PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage biotechnology company developing cell-based therapies for chronic kidney disease, with its lead program REACT (Renal Autologous Cell Therapy) designed to slow disease progression using a patient's own renal cells. The company entered the public markets in January 2022 through a business combination with Social Capital Suvretta Holdings Corp. I, a blank-check vehicle sponsored by Social Capital and Suvretta Capital Management whose SPAC IPO priced in 2021. The 10-Q filed with the SEC on May 16, 2022 represents one of ProKidney's first quarterly disclosures as a publicly traded entity in the healthcare and biotechnology sector. Sign up on SpacDesk for full filing history, sponsor data, and deal timelines across thousands of SPAC transactions.